Healthcare Professionals   /   Conferences   /   Conference and Meeting Announcements   /   2005   /   February

Fifth Annual Targeted Therapies for the Treatment of Lung Cancer

Last Modified: December 3, 2004

Conference Dates: February 10-12, 2005
Conference Location: Steamboat Springs, Colorado

Sponsoring Group: The Dannemiller Memorial Educational Foundation and Cadent Medical Communications

Conference Web Page URL: http:/www.thecbce.com/futureprograms.asp

Topics Covered: After participating in this conference, attendees should be able to:

1. Explain the current understanding of the pathogenesis of lung cancer and rationale for use of novel targeted agents in the treatment of lung cancer.
2. Describe the integration of targeted agents into the standard treatment paradigm for NSCLC and utilize these regimens where possible to improve patient outcome.
3. Utilize recent data on the use of prognostic indicators in determining treatment for lung cancer patients and recent finds regarding DNA mutations to select appropriate therapy for your NSCLC patients.
4. Optimize the use of radiation therapy when combined with targeted therapy in your lung cancer patients.
5. Restate the preclinical and clinical rationale for combining different targeted therapies in lung cancer.
6. Recognize methods for surrogate analysis of tissue imaging that can be used to guide clinical trials of targeted agents.

Conference Objectives:

1. Explain the current understanding of the pathogenesis of lung cancer and rationale for use of novel targeted agents in the treatment of lung cancer.
2. Describe the integration of targeted agents into the standard treatment paradigm for NSCLC and utilize these regimens where possible to improve patient outcome.
3. Utilize recent data on the use of prognostic indicators in determining treatment for lung cancer patients and recent finds regarding DNA mutations to select appropriate therapy for your NSCLC patients.
4. Optimize the use of radiation therapy when combined with targeted therapy in your lung cancer patients.
5. Restate the preclinical and clinical rationale for combining different targeted therapies in lung cancer.
6. Recognize methods for surrogate analysis of tissue imaging that can be used to guide clinical trials of targeted agents.

Who Should Attend: This activity is intended for medical oncologists and other physicians interested in the treatment of lung cancer.

Registration Information: Please see web page www.thecbce.com/futureprograms.asp

Conference Fees: Please see web page www.thecbce.com/futureprograms.asp

Continuing Education: Yes